Central Texas Nurse Practitioners

Navigating the Complex Treatment Landscape of Intermediate and Advanced HCC: A Think Tank Activity

CE Information
1.0 CME credit
Completion Time
1 hour
Available Until
September 26, 2025
Posted By
Integrity CE
Integrity CE Integrity CE
Ready to start this activity?
Login required. You will be redirected to an external website to register for and complete this activity.

Overview

Specialties
Oncology
Subspecialties
Gastroenterology and Radiology
Clinical Topics
Oncology

With the accelerated expansion of the treatment landscape of intermediate and advanced hepatocellular carcinoma (HCC), several practical challenges have emerged in clinical practice. An example of this is the challenge of identifying patients with intermediate HCC who would benefit from local-regional treatment with TACE/TARE or a combination approach with TACE/TARE + IO. Multidisciplinary care is critical to optimize outcomes for these patients.

This program features a moderated discussion among a panel of experts: a surgeon, a hepatologist, and a medical oncologist, all involved in the management and treatment of patients with HCC.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Implement novel first-line regimens, including multimodal combination and sequential treatment strategies, in the treatment of patients with intermediate HCC based on emerging evidence from clinical trials
  • Integrate emerging therapies and novel combination regimens in the treatment of patients with advanced HCC to improve treatment outcomes

Speakers

Michael Pishvaian
Michael Pishvaian MD, PhD

Director of Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs
Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital
Johns Hopkins University School of Medicine
Washington, District of Columbia

Richard S. Finn
Richard S. Finn MD

Professor of Medicine, Hematology/Oncology
Geffen School of Medicine at UCLA
Director, Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

Riad Salem
Riad Salem MD

Professor of Radiology, Medicine, and Surgery
Vice-Chair, Image-Guided Therapy
Chief, Vascular and Interventional Radiology
Northwestern University
Chicago, Illinois

Amit Singal
Amit Singal MD, MS

Professor of Medicine
Chief of Hepatology and Director of Liver Tumor Program
UT Southwestern Medical Center
Dallas, Texas

CE Information

This activity offers 1.0 CME credit to attendees.

Accredited by Integrity CE, LLC (ACCME).

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is provided by Integrity CE, LLC.

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Disclosures

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Richard S. Finn, MD
Consultant: AstraZeneca, Bayer, CStone, Eisai, Eli Lilly, Exelixis, Merck, Novartis, Pfizer, Roche/Genentech, Zai Labs
Research Grants: Bayer, Eisai, Eli Lilly, Pfizer, Merck, Roche/Genentech

Michael Pishvaian, MD, PhD
Ad Hoc Advisory Boards: AstraZeneca, Ideaya, Merck, Merus, Seattle Genetics
Steering Committees: Astellas, Merck, Renovo Rx
CME Activity: Astellas
Travel: Astellas, Renovo Rx
Stock: Perthera

Riad Salem, MD
Consultant: AstraZeneca, Becton Dickinson, Boston Sciences, Cook, Eisai, Genentech, Siemens, Sirtex, Terumo

Amit Singal, MD, MS
Consultant: AstraZeneca, Bayer, Boston Scientific, Eisai, Exact Sciences, Exelixis, FujiFilm Medical Sciences, Glycotest, HistoSonics, Merck Genentech, Sirtex

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Ready to start this activity?

Login required. You will be redirected to an external website to register for and complete this activity.

Log in and start activity